Leerink Partnrs Has Positive Estimate for NRIX Q3 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Leerink Partnrs raised their Q3 2025 earnings estimates for shares of Nurix Therapeutics in a report issued on Wednesday, July 9th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will earn ($0.96) per share for the quarter, up from their prior forecast of ($0.99). The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics' Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.14) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($1.09) EPS, Q3 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($1.01) EPS and FY2026 earnings at ($4.27) EPS.

Several other analysts also recently commented on the stock. UBS Group dropped their target price on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, July 10th. Stifel Nicolaus dropped their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Oppenheimer set a $30.00 price target on shares of Nurix Therapeutics and gave the stock an "outperform" rating in a research note on Thursday, July 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Finally, HC Wainwright decreased their price target on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $29.31.

Nurix Therapeutics Trading Up 1.5%

Shares of NASDAQ:NRIX traded up $0.19 during mid-day trading on Monday, reaching $12.34. The stock had a trading volume of 363,874 shares, compared to its average volume of 847,764. The firm has a market cap of $943.23 million, a PE ratio of -4.72 and a beta of 2.15. The firm has a 50 day simple moving average of $11.32 and a two-hundred day simple moving average of $13.71. Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. The company had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its holdings in shares of Nurix Therapeutics by 2.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock worth $585,000 after purchasing an additional 642 shares during the last quarter. Corebridge Financial Inc. raised its position in shares of Nurix Therapeutics by 2.3% during the fourth quarter. Corebridge Financial Inc. now owns 34,907 shares of the company's stock worth $658,000 after purchasing an additional 770 shares during the period. Kennedy Capital Management LLC raised its position in Nurix Therapeutics by 0.7% in the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company's stock valued at $2,159,000 after buying an additional 785 shares during the last quarter. US Bancorp DE raised its position in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after buying an additional 842 shares during the last quarter. Finally, Summit Investment Advisors Inc. grew its stake in Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after purchasing an additional 877 shares during the period.

Insiders Place Their Bets

In other news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the sale, the insider owned 61,516 shares of the company's stock, valued at approximately $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the transaction, the chief financial officer directly owned 33,724 shares of the company's stock, valued at approximately $382,092.92. This trade represents a 15.53% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,013 shares of company stock valued at $137,096 in the last three months. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.